Angiotensin-(1-7) exhibits depressor, vasodilator, and antihypertensive actions that oppose the effects of Angiotensin II, potentially by increasing prostaglandins or nitric oxide.
Angiotensin-(1-7) acts as a counter-regulatory peptide to Angiotensin II, exhibiting vasodilator and antihypertensive effects.
Accumulating evidence suggests that angiotensin-(1-7)(Ang-(1-7)) is an important component of the renin-angiotensin system and that the actions of the peptide may either contribute to or oppose those of Ang II. Ang-(1-7) can be converted directly from Ang I bypassing prerequisite formation of Ang II. Formation of Ang-(1-7) is under the control of at least three endopeptidases depending on the tissue compartment and include neprilysin, thimet oligopeptidase and prolyl oligopeptidase. Both neprilysin and thimet oligopeptidase are also involved in the metabolism of bradykinin and the atrial natriuretic peptide. Moreover, recent studies suggest that in addition to Ang I and bradykinin, Ang-(1-7) is an endogenous substrate for angiotensin converting enzyme. These enzymatic pathways may contribute to a complex relationship between the hypertensive actions of Ang II and various vasodepressor peptides from either the renin-angiotensin system or other peptide systems. Ang-(1-7) is devoid of the vasoconstrictor, central pressor, or thirst-stimulating actions associated with Ang II. In fact, new findings reveal depressor, vasodilator, and antihypertensive actions that may be more apparent in hypertensive animals or humans. Thus, Ang-(1-7) may oppose the actions of Ang II directly or as a result of increasing prostaglandins or nitric oxide. In this review, we examine the mechanisms by which Ang-(1-7) may contribute to cardiovascular regulation.
Chappell et al. (1998) conducted a review in Hypertension. Angiotensin-(1-7) was evaluated. Angiotensin-(1-7) exhibits depressor, vasodilator, and antihypertensive actions that oppose the effects of Angiotensin II, potentially by increasing prostaglandins or nitric oxide.